Skip to main content

Advertisement

Table 4 Secondary analysis: cSMS and RCSS of AIT with DPAEs compared with placebo (all study seasons)

From: Subcutaneous immunotherapy with depigmented-polymerized allergen extracts: a systematic review and meta-analysis

Study subgroups GINA + ARIA score Study subgroups Efficacy evaluation period cSMS as primary All cSMS All RCSS
Intermittent asthma
Any rhinoconjunctivitis severity
0 Pfaar, 2010 (Pollen) 24 mo. (Primary) 0.4 (0.1 to 0.7) 0.4 (0.1 to 0.7) 0.4 (0.1 to 0.7)
Intermittent to mild asthma
Moderate to severe rhinoconjunctivitis
1 Pfaar, 2012 (Pollen) 24 mo. (Primary)
12 mo. (Secondary)
1.1 (0.9 to 1.3) 1.1 (0.9 to 1.2) 1.3 (0.7 to 1.9)
   Pfaar, 2013 (Pollen) 24 mo. (Primary)
12 mo. (Secondary)
   
   Colás, 2006 (Pollen) 12 mo. (Primary)    
   Höiby, 2010 (Pollen) 24 mo. (Primary)    
Intermittent to moderate asthma
or
Moderate to severe rhinoconjunctivitis
2 Alvarez-Cuesta, 2005 (Pollen) 12 mo. (Primary) 2.6 (2.1 to 3.1) 2.6 (2.1 to 3.1) 2.3 (1.8 to 2.8)
  Ameal, 2005 (HDM) 12 mo. (Primary)    
Intermittent to moderate asthma
&
Moderate to severe rhinoconjunctivitis
3 García-Robaina, 2006 (HDM) 12 mo. (Primary) 5.1 (3.9 to 6.2) 5.1 (3.9 to 6.2) 4.4 (3.4to 5.4)
  1. 95% CI 95% confidence interval, AIT allergen specific immunotherapy, ARIA Allergic Rhinitis and its Impact on Asthma, cSMS combined symptom and medication score, GINA Global Initiative for Asthma, HDM house dust mite, mo months, RCSS rhinoconjunctivitis symptom score, SD standard deviation, SMD standardized mean differences